![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, October 08, 2021 8:42:26 PM
October 8, 2021
A clinical trial evaluating oral Anavex 2-73 in children and teenagers with Rett syndrome is recruiting up to 84 girls, ages 5 to 17, at a center in Vancouver, Canada, and three sites in Australia.
According to a press release from the Ontario Rett Syndrome Association, the British Columbia Children’s Hospital site marks the first Rett syndrome trial in Canada.
The Phase 2/3 study (NCT04304482), called EXCELLENCE, will run for 12 weeks with patients randomly assigned in a 2:3 ratio to either Anavex 2-73 or a placebo. Those eligible must have a confirmed Rett diagnosis, and be at least six months out from their last loss of language or fine or gross motor skills.
Anavex Life Sciences, the therapy’s developer, is sponsoring the study. More information on trial sites and contacts can be found using this link.
Anavex 2-73 is a liquid, oral medication that has been shown to activate a protein called the sigma-1 receptor, which is known to help proteins fold properly. By activating this receptor, Anavex 2-73 has the potential to reduce protein misfolding within cells and prevent some of the neuroinflammation and neurological (emotional, sensory, motor, and cognitive) problems seen in people with Rett.
The disease almost exclusively affects females.
Results of a Phase 2 trial of Anavex 2-73 in 31 women in the U.S. (NCT03758924) showed that about two-thirds of treated patients (ages 18 to 45) had a significant reduction in several characteristic Rett behaviors, including general mood, breathing, hand behavior, and repetitive face movements.
The EXCELLENCE trial’s main goals are changes in characteristic behaviors from the study’s start (baseline) through 12 weeks, as assessed using the Rett Syndrome Behavior Questionnaire, in addition to treatment safety.
Secondary trial goals will include changes over the study’s course in measures of anxiety, depression and mood; in sleep habits and seizure frequency; and in motor behavior. Caregivers’ views of treatment effectiveness will also be assessed.
The trial requires participants to complete four in-person visits, and four checkups done by phone. Travel expenses related to in-person visits will be reimbursed by the study, the release stated.
Study visits will include collection of blood and urine samples, electrocardiograms to measure the electrical activity of the heart, physical exams, and questionnaires to be completed by the patients’ caregivers.
Patients who complete the main trial will be offered the option of entering its 48-week open label extension (OLE), in which all will be given Anavex 2-73 (no placebo group).
The three Australian sites are at centers in Sydney, Brisbane, and Melbourne.
People in Canada wanting more information about the trial may also contact Sabrina Millson, president of the Ontario Rett Syndrome Association, at smillson@rett.ca.
EXCELLENCE is due to conclude in June 2022.
https://rettsyndromenews.com/2021/10/08/phase-2-3-trial-of-anavex-2-73-enrolling-girls-in-canada-australia/
Good luck and GOD bless,
Recent AVXL News
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
Kona Gold Beverages, Inc. Announces Strategic Initiatives and Corporate Direction Changes • KGKG • Aug 2, 2024 2:00 PM
POET and Luxshare Tech Expand Product Offerings for Artificial Intelligence Networks • POET • Aug 1, 2024 9:28 AM
Management Discusses Financial Filings of Global Arena Holding Inc., for 10-K 2023 and 10-Q, 1st Quarter 2024 • GAHC • Aug 1, 2024 9:14 AM
VAYK Announces LOI to Acquire $1 Million Home Service Company to Support Airbnb Business • VAYK • Aug 1, 2024 9:00 AM
Duane Forrester Joins INDEXR as SVP of Search • MONI • Jul 31, 2024 11:46 AM
Lingerie Fighting Championships Help Fulfill Death-Bed Promise With First Major Motion Picture • BOTY • Jul 31, 2024 9:00 AM